Author: Oryn Therapeutics

Oryn Therapeutics Advances Next Phase of Orynotide™ Macrocyclic Peptide Platform Development with Expanded Leadership Team and Board Anchored by Accomplished Life Sciences Industry Veterans, Company Builders and Drug Developers

June 23, 2026

Oryn Therapeutics Advances Next Phase of Orynotide™ Macrocyclic Peptide Platform Development with Expanded Leadership Team and Board Anchored by Accomplished Life Sciences Industry Veterans, Company Builders and Drug Developers